The global oral hypoglycemics market is expected to grow at a CAGR of 4.5% during the forecast period, from 2021 to 2030. The growth in this market is attributed to the increasing prevalence of diabetes and obesity, which are major risk factors for type 2 diabetes mellitus (T2DM). The increasing number of people with T2DM has led to an increase in the demand for oral hypoglycemic agents. The global oral hypoglycemics market is segmented by type, application and region. On the basis of type, it can be classified into sulfonylureas, metformin, thiazolidinediones and alphglucosidase inhibitors. On the basis of application it can be classified into hospitals and clinics. On the basis of region it can be classified into North America, Latin America, Europe Asia Pacific and Middle East & Africa regions.
- The global Oral Hypoglycemics market is driven by factors such as increasing prevalence of diabetes and obesity, rising awareness about the benefits of OHAs, and growing demand for oral hypoglycemic agents in emerging economies such as China and India.
- Increasing prevalence of diabetes and obesity: Diabetes is a chronic disease that affects the way your body uses sugar (glucose). It can lead to serious health problems if not managed properly, including heart disease, stroke, blindness or kidney failure.
- Rising awareness about the benefits of OHAs: Awareness about the benefits of OHAs has increased due to various campaigns undertaken by pharmaceutical companies in order to educate people on how they can manage their blood sugar levels with these drugs.
- Growing demand for oral hypoglycemic agents in emerging economies: Emerging economies such as China and India are witnessing an increase in demand for oral hypoglycemic agents due to increasing incidence rates among diabetic patients.
Industry Growth Insights published a new data on “Oral Hypoglyceimic Agents (OHAs) Market”. The research report is titled “Oral Hypoglyceimic Agents (OHAs) Market research by Types (Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors), By Applications (Hospitals and Clinics, Others), By Players/Companies Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Hypoglyceimic Agents (OHAs) Market Research Report
By Type
Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors
By Application
Hospitals and Clinics, Others
By Companies
Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Oral Hypoglyceimic Agents (OHAs) Market Report Segments:
The global Oral Hypoglyceimic Agents (OHAs) market is segmented on the basis of:
Types
Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- GlaxoSmithKline
- Bayer
- Bristol-Myers Squibb
- Novonordisk
- Sanofi-Aventis
- Servier
- Huadong Medicine
- Wanbang Biopharmaceuticals
- Double-Crane Pharmaceutical
- Guangzhou Pharmaceutical
Highlights of The Oral Hypoglyceimic Agents (OHAs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sulfonylureas
- Metformin
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- By Application:
- Hospitals and Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Hypoglyceimic Agents (OHAs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral hypoglyceimics are medications that help to lower blood sugar levels. They are often used in combination with other treatments, such as insulin, to manage diabetes.
Some of the major players in the oral hypoglyceimic agents (ohas) market are Pfizer, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novonordisk, Sanofi-Aventis, Servier, Huadong Medicine, Wanbang Biopharmaceuticals, Double-Crane Pharmaceutical, Guangzhou Pharmaceutical.
The oral hypoglyceimic agents (ohas) market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oral Hypoglyceimic Agents (OHAs) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oral Hypoglyceimic Agents (OHAs) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oral Hypoglyceimic Agents (OHAs) Market - Supply Chain
4.5. Global Oral Hypoglyceimic Agents (OHAs) Market Forecast
4.5.1. Oral Hypoglyceimic Agents (OHAs) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oral Hypoglyceimic Agents (OHAs) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oral Hypoglyceimic Agents (OHAs) Market Absolute $ Opportunity
5. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
5.3.1. Sulfonylureas
5.3.2. Metformin
5.3.3. Thiazolidinediones
5.3.4. Alpha-Glucosidase Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
6.3.1. Hospitals and Clinics
6.3.2. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oral Hypoglyceimic Agents (OHAs) Demand Share Forecast, 2019-2026
9. North America Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
9.4.1. Hospitals and Clinics
9.4.2. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
9.7.1. Sulfonylureas
9.7.2. Metformin
9.7.3. Thiazolidinediones
9.7.4. Alpha-Glucosidase Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oral Hypoglyceimic Agents (OHAs) Demand Share Forecast, 2019-2026
10. Latin America Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
10.4.1. Hospitals and Clinics
10.4.2. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
10.7.1. Sulfonylureas
10.7.2. Metformin
10.7.3. Thiazolidinediones
10.7.4. Alpha-Glucosidase Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oral Hypoglyceimic Agents (OHAs) Demand Share Forecast, 2019-2026
11. Europe Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
11.4.1. Hospitals and Clinics
11.4.2. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
11.7.1. Sulfonylureas
11.7.2. Metformin
11.7.3. Thiazolidinediones
11.7.4. Alpha-Glucsidase Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oral Hypoglyceimic Agents (OHAs) Demand Share, 2019-2026
12. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
12.4.1. Hospitals and Clinics
12.4.2. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
12.7.1. Sulfonylureas
12.7.2. Metformin
12.7.3. Thiazolidinediones
12.7.4. Alpha-Glucosidase Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oral Hypoglyceimic Agents (OHAs) Demand Share, 2019-2026
13. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Application
13.4.1. Hospitals and Clinics
13.4.2. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Market Size and Volume Forecast by Type
13.7.1. Sulfonylureas
13.7.2. Metformin
13.7.3. Thiazolidinediones
13.7.4. Alpha-Glucosidase Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oral Hypoglyceimic Agents (OHAs) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oral Hypoglyceimic Agents (OHAs) Market: Market Share Analysis
14.2. Oral Hypoglyceimic Agents (OHAs) Distributors and Customers
14.3. Oral Hypoglyceimic Agents (OHAs) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novonordisk
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi-Aventis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Servier
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Huadong Medicine
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Wanbang Biopharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Double-Crane Pharmaceutical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Guangzhou Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook